Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 124 articles: HTML format

Single Articles

April 2026
1. NG DQ, Heshmatipour M, Trudeau J, Sridhar A, et al
   Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.
   J Natl Cancer Inst. 2026 Apr 2:djag096. doi: 10.1093.
   PubMed     Abstract available
   
   
   March 2026
2. KAUL M, Scott CG, Wadzinske A, Banerjee I, et al
   Performance of clinical breast cancer risk prediction models versus a mammography-based artificial intelligence risk model.
   J Natl Cancer Inst. 2026 Mar 26:djag083. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. KWAN ML, D'Addario L, Lee C, Roh JM, et al
   Differences in breast cancer survival across Asian American ethnicities compared with non-Latina White females in Kaiser Permanente Northern California.
   J Natl Cancer Inst. 2026 Mar 26:djag062. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. ABOUMRAD M, Joshu C, Jackson J, Visvanathan K, et al
   Antidepressant adherence and breast cancer recurrence risk in women with major depressive disorder: a retrospective cohort.
   J Natl Cancer Inst. 2026 Mar 21:djag076. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. YADAV S, Reid S, Yilma B, Fragkogianni S, et al
   Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes.
   J Natl Cancer Inst. 2026 Mar 14:djag070. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. SAMPATHKUMAR Y, Zakaria Z, O'Connell K, Bhimani J, et al
   Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.
   J Natl Cancer Inst. 2026 Mar 4:djag063. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2026
7. WOOLPERT KM, Kjaersgaard A, Schapira L, Toft Sorensen H, et al
   Opioid use after breast cancer in Denmark: a nationwide study of social and clinical factors.
   J Natl Cancer Inst. 2026 Feb 25:djag052. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. DANIELSSON O, Dar H, Nordenskjold A, Perez-Tenorio G, et al
   Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
   J Natl Cancer Inst. 2026 Feb 19:djag049. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. TICKLE A, Offman J, North B, Jorgensen SF, et al
   Improved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study.
   J Natl Cancer Inst. 2026 Feb 19:djaf377. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. KORIC A, Bennett DL, Boulos F, Colditz GA, et al
    Subsequent breast cancer risk after benign biopsy in racially diverse women: Siteman Cancer Center.
    J Natl Cancer Inst. 2026 Feb 16:djag048. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. RICHMAN IB, Lindsay ME, Long JB, Epstein E, et al
    Diagnostic yield of surveillance mammography among older women.
    J Natl Cancer Inst. 2026;118:223-230.
    PubMed     Abstract available
    
    
    
12. TUNG N, Hollis RL, Viale G, Tweed C, et al
    Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.
    J Natl Cancer Inst. 2026;118:205-213.
    PubMed     Abstract available
    
    
    January 2026
13. PIMENTEL-PARRA GA, Soto-Ruiz N, Escalada-Hernandez P, San Martin-Rodriguez L, et al
    EHealth intervention for quality of life in long-term breast cancer survivors: Randomized controlled trial.
    J Natl Cancer Inst. 2026 Jan 24:djag020. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. SHERMAN ME, Etievant L, Vierkant RA, Winham SJ, et al
    Postpartum breast cancer: evidence for a distinct phenotype.
    J Natl Cancer Inst. 2026 Jan 9:djag003. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. LEHRER S
    Re: Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
    J Natl Cancer Inst. 2026 Jan 8:djaf339. doi: 10.1093.
    PubMed    
    
    
    
16. LOWRY KP, Jeong HE, Kim KH, Hughes KS, et al
    Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review.
    J Natl Cancer Inst. 2026 Jan 7:djag002. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. IM C, Hasan H, Srinivasan A, Stene E, et al
    Breast cancer recurrence and mortality among survivors of childhood cancer.
    J Natl Cancer Inst. 2026 Jan 7:djag005. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. WESTVOLD SJ, Long JB, Fan J, Kc M, et al
    Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.
    J Natl Cancer Inst. 2026;118:130-140.
    PubMed     Abstract available
    
    
    
19. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
    Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
    J Natl Cancer Inst. 2026;118:94-101.
    PubMed     Abstract available
    
    
    December 2025
20. SHAO L, Wang Y, Shieh Y, Tamimi RM, et al
    Second primary cancer in breast cancer survivors by race/ethnicity and asian subgroups: a descriptive epidemiologic study.
    J Natl Cancer Inst. 2025 Dec 23:djaf372. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. SEMPRINI J
    RE: Ambient air pollution and mortality in older patients with breast cancer.
    J Natl Cancer Inst. 2025 Dec 17:djaf369. doi: 10.1093.
    PubMed    
    
    
    
22. KOTSOPOULOS J, Seca M, Gronwald J, Huzarski T, et al
    Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.
    J Natl Cancer Inst. 2025 Dec 17:djaf363. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. JOURQUIN J, Dickerson JC, Marks EG, Epps J, et al
    Susan G. Komen's ShareForCures(R): a patient-engaged, nationwide breast cancer research registry.
    J Natl Cancer Inst. 2025 Dec 13:djaf353. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. MATTICK LJ, Li CS, Lin PJ, Peppone LJ, et al
    Walking dose associated with lower cancer-related fatigue among patients with breast cancer.
    J Natl Cancer Inst. 2025 Dec 13:djaf360. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. HU X, Cai C, Arshad S, Anderson JN, et al
    Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.
    J Natl Cancer Inst. 2025 Dec 9:djaf301. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. SHUMWAY DA, Corbin KS, Shiraishi S, Farah MH, et al
    Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation.
    J Natl Cancer Inst. 2025 Dec 6:djaf346. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. NASSAR AH, Bou Farhat E, Abushukair H, Alchoueriy M, et al
    Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.
    J Natl Cancer Inst. 2025 Dec 4:djaf344. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. HAZELWOOD E, Goudswaard LJ, Lee MA, Vabistsevits M, et al
    Adiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis.
    J Natl Cancer Inst. 2025;117:2621-2642.
    PubMed     Abstract available
    
    
    November 2025
29. CHOI E, Zhai W, Ahn J, Ahles TA, et al
    Neighborhood deprivation on increasing deficit accumulation in older breast cancer survivors and non-cancer controls.
    J Natl Cancer Inst. 2025 Nov 22:djaf337. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. WORTELBOER N, Kent S, Blommestein HM, van Ommen-Nijhof A, et al
    Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.
    J Natl Cancer Inst. 2025 Nov 21:djaf334. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. ORLANDI A
    RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
    J Natl Cancer Inst. 2025 Nov 5:djaf319. doi: 10.1093.
    PubMed    
    
    
    
32. AIELLO BOWLES EJ, O'Connell K, Bhimani J, Gallagher GB, et al
    Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer.
    J Natl Cancer Inst. 2025 Nov 3:djaf314. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. LIU Q, Wiese D, Pinheiro PS, Bispo JB, et al
    Association between racialized economic segregation and stage at diagnosis for 3 screenable cancers in New York City.
    J Natl Cancer Inst. 2025;117:2259-2271.
    PubMed     Abstract available
    
    
    
34. VO JB, Brown DW, Buller ID, Shing JZ, et al
    Associations of self-identified race and ethnicity and genetic ancestry with mortality among cancer survivors.
    J Natl Cancer Inst. 2025;117:2382-2387.
    PubMed     Abstract available
    
    
    October 2025
35. 
    Correction to: Discovering plasma proteins associated with breast cancer incidence in postmenopausal women in the Atherosclerosis Risk in Communities study.
    J Natl Cancer Inst. 2025 Oct 17:djaf284. doi: 10.1093.
    PubMed    
    
    
    
36. OTTAVIANI D, Ola M, Allotta A, Maati Chaibi Y, et al
    Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
    J Natl Cancer Inst. 2025 Oct 15:djaf295. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. NADER-MARTA G, Chu X, Mukhopadhyay S, Abramson VG, et al
    Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
    J Natl Cancer Inst. 2025 Oct 11:djaf289. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. NGUYEN THT, Jeon S, Yoon J, Park B, et al
    Independent associations between obesity, glucose metabolism, and breast cancer risk through unrelated pathways.
    J Natl Cancer Inst. 2025 Oct 8:djaf287. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2025
39. SYMONDS LK, Davidson NE
    RecOVARY? Using anti-Mullerian hormone to predict ovarian function after anti-HER2 therapy for early breast cancer.
    J Natl Cancer Inst. 2025 Sep 26:djaf247. doi: 10.1093.
    PubMed    
    
    
    
40. SEEWALDT VL, Schedin PJ
    Breastfeeding after breast cancer: a need for further mechanistic study.
    J Natl Cancer Inst. 2025 Sep 18:djaf240. doi: 10.1093.
    PubMed    
    
    
    
41. IRAJIZAD E, Hanash S
    Breast cancer risk assessment: current challenges and the emerging role of blood-based protein biomarkers.
    J Natl Cancer Inst. 2025 Sep 3:djaf215. doi: 10.1093.
    PubMed    
    
    
    
42. PRESTI D, Di Meglio A, Havas J, Pagliuca M, et al
    Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort.
    J Natl Cancer Inst. 2025 Sep 3:djaf256. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. SAHIN TK, Guven DC, Aksoy S
    RE: Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
    J Natl Cancer Inst. 2025 Sep 3:djaf254. doi: 10.1093.
    PubMed    
    
    
    August 2025
44. CARBONE A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, et al
    Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer.
    J Natl Cancer Inst. 2025 Aug 28:djaf250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. TARANTINO P, Lee D, Foldi J, Soulos PR, et al
    Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
    J Natl Cancer Inst. 2025 Aug 14:djaf220. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. LAMBERTINI M, Allegranza D, Laubender RP, Harbeck N, et al
    Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
    J Natl Cancer Inst. 2025 Aug 12:djaf198. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. MO T, Partridge A, Joffe M, Cubasch H, et al
    Survival deficits in young women with breast cancer in Sub-Saharan africa: the ABC-DO cohort.
    J Natl Cancer Inst. 2025 Aug 7:djaf213. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. WEI Y, Castro E, Yin K, Zhang M, et al
    Ambient air pollution and mortality in older breast cancer patients.
    J Natl Cancer Inst. 2025 Aug 5:djaf217. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. SPOOR J, Mureau MAM, Tissier RLM, Hommes J, et al
    Breast implant illness after reconstruction with silicone breast implants.
    J Natl Cancer Inst. 2025;117:1717-1728.
    PubMed     Abstract available
    
    
    
50. YU TT, Hoyt AC, Joines MM, Fischer CP, et al
    Mammographic classification of interval breast cancers and artificial intelligence performance.
    J Natl Cancer Inst. 2025;117:1627-1638.
    PubMed     Abstract available
    
    
    July 2025
51. ZHU T, Bu J, Zhu X
    RE: Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
    J Natl Cancer Inst. 2025 Jul 23:djaf187. doi: 10.1093.
    PubMed    
    
    
    
52. WATT GP, Reiner AS, Shu X, Malone KE, et al
    Polygenic risk of coronary artery disease for long-term survivors of breast cancer.
    J Natl Cancer Inst. 2025 Jul 16:djaf189. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. BOTTERI E, Hjorth S, Conforti F, Bagnardi V, et al
    Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
    J Natl Cancer Inst. 2025 Jul 14:djaf178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. SYLEOUNI ME, Joshu CE, Coresh J, Gunter MJ, et al
    Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC.
    J Natl Cancer Inst. 2025 Jul 7:djaf170. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. BLONDEAUX E, Delucchi V, Mariamidze E, Bernstein-Molho R, et al
    Breastfeeding after breast cancer in young BRCA carriers.
    J Natl Cancer Inst. 2025 Jul 7:djaf177. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. STECKLEIN SR, Martin M, Villacampa G, Del Monte-Millan M, et al
    Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
    J Natl Cancer Inst. 2025 Jul 2:djaf162. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
    Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2025;117:1506-1511.
    PubMed     Abstract available
    
    
    June 2025
58. ARECCO L, Blondeaux E, Bruzzone M, Arpino G, et al
    Prognostic implications of risk definitions from the monarchE and NATALEE trials.
    J Natl Cancer Inst. 2025;117:1198-1208.
    PubMed     Abstract available
    
    
    May 2025
59. ABUBAKAR M, Duggan MA, Fan S, Pfeiffer RM, et al
    Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes.
    J Natl Cancer Inst. 2025 May 14:djaf070. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. LI D, Liu Y, Duan Q, Chen X, et al
    RE: Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
    J Natl Cancer Inst. 2025 May 7:djaf115. doi: 10.1093.
    PubMed    
    
    
    
61. TUESLEY KM, Spilsbury K, Pearson SA, Donovan P, et al
    Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
    J Natl Cancer Inst. 2025;117:1046-1055.
    PubMed     Abstract available
    
    
    
62. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    PubMed     Abstract available
    
    
    
63. BUQUE A, Bloy N, Petroni G, Jimenez-Cortegana C, et al
    Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor-positive mammary carcinogenesis.
    J Natl Cancer Inst. 2025;117:934-947.
    PubMed     Abstract available
    
    
    April 2025
64. ZHANG J, Zhang L, Liu Z, Jia Y, et al
    RE: Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
    J Natl Cancer Inst. 2025 Apr 9:djaf093. doi: 10.1093.
    PubMed    
    
    
    
65. LOPEZ-FERNANDEZ A, Duran-Lozano L, Villacampa G, Pardo M, et al
    A randomized study of 2 risk assessment models for individualized breast cancer risk estimation.
    J Natl Cancer Inst. 2025 Apr 1:djaf067. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. BARGON CA, Mink van der Molen DR, Young-Afat DA, Batenburg MCT, et al
    Clinical and patient-reported outcomes after oncoplastic vs conventional breast-conserving surgery-a longitudinal, multicenter cohort study.
    J Natl Cancer Inst. 2025;117:781-789.
    PubMed     Abstract available
    
    
    
67. LI S, Madanat-Harjuoja L, Leslie G, Barnes DR, et al
    Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:728-736.
    PubMed     Abstract available
    
    
    
68. STROOT IAS, Bart J, Hollema H, Wagner MM, et al
    High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:719-727.
    PubMed     Abstract available
    
    
    
69. HAMMARSTROM M, Gabrielson M, Bergqvist J, Lundholm C, et al
    Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.
    J Natl Cancer Inst. 2025;117:629-636.
    PubMed     Abstract available
    
    
    March 2025
70. KURIAN AW, Furgal AKC, Radhakrishnan A, Veenstra CM, et al
    Extended endocrine therapy use and decision making after breast cancer diagnosis.
    J Natl Cancer Inst. 2025 Mar 31:djaf076. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. SAMMONS SL, Sanglier T, Leone JP, Erick TK, et al
    Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients.
    J Natl Cancer Inst. 2025 Mar 31:djaf048. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. LYNCE F, Niman SM, Kai M, Ma SR, et al
    Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic Score.
    J Natl Cancer Inst. 2025 Mar 31:djaf088. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. BETTARIGA F, Taaffe DR, Borsati A, Avancini A, et al
    Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis.
    J Natl Cancer Inst. 2025 Mar 20:djaf062. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. HUANG Y, Kwan ML, Heckbert SR, Smith NL, et al
    Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
    J Natl Cancer Inst. 2025 Mar 11:djaf063. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
75. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    PubMed     Abstract available
    
    
    January 2025
76. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
    NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
    J Natl Cancer Inst. 2025;117:120-133.
    PubMed     Abstract available
    
    
    
77. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
    Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
    J Natl Cancer Inst. 2025;117:188-197.
    PubMed     Abstract available
    
    
    
78. GANZ PA, Cecchini RS, White JR, Vicini FA, et al
    Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.
    J Natl Cancer Inst. 2025;117:103-111.
    PubMed     Abstract available
    
    
    December 2024
79. ZHANG Y, Lv P
    RE: Genetic risk, health-associated lifestyle, and risk of early-onset total cancer and breast cancer.
    J Natl Cancer Inst. 2024 Dec 19:djae322. doi: 10.1093.
    PubMed    
    
    
    
80. LOLAS-HAMAMEH S, Lieberman S, Sarahneh A, Walsh T, et al
    TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers.
    J Natl Cancer Inst. 2024 Dec 14:djae334. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. PETITJEAN C, Wilcox N, Ficorella L, Dennis J, et al
    Evaluating the performance of the BOADICEA model in predicting 10-year breast cancer risks in UK Biobank.
    J Natl Cancer Inst. 2024 Dec 12:djae335. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. ABDOU Y, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
    J Natl Cancer Inst. 2024 Dec 5:djae314. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. PALMER S, Valachis A, Lindman H, Smith DR, et al
    Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer.
    J Natl Cancer Inst. 2024 Dec 4:djae315. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. JOHANSSON A, Dar H, Nordenskjold A, Perez-Tenorio G, et al
    Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
    J Natl Cancer Inst. 2024 Dec 4:djae268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. SERRANO D, Johansson H, Bertelsen BE, Gandini S, et al
    Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules.
    J Natl Cancer Inst. 2024;116:1979-1982.
    PubMed     Abstract available
    
    
    
86. ARTESE AL, Zhou X, Tometich DB, Small BJ, et al
    Physical activity and cognition: longitudinal findings from the Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2024;116:2009-2021.
    PubMed     Abstract available
    
    
    
87. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
    Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
    J Natl Cancer Inst. 2024;116:1904-1913.
    PubMed     Abstract available
    
    
    November 2024
88. GRAFF SL, Tinianov S, Kalinsky K
    "Nailing down" risk and improving outcomes in early-stage breast cancer.
    J Natl Cancer Inst. 2024 Nov 22:djae278. doi: 10.1093.
    PubMed    
    
    
    
89. ROMANOS-NANCLARES A, Willett WC, Rosner B, Stover DG, et al
    Proinflammatory Dietary Pattern and Risk of Total and Subtypes of Breast Cancer Among U.S. Women.
    J Natl Cancer Inst. 2024 Nov 20:djae301. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. ABOUMRAD M, Joshu C, Visvanathan K
    Impact of major depressive disorder on breast cancer outcomes: a national retrospective cohort study.
    J Natl Cancer Inst. 2024 Nov 12:djae287. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. ROBERTI S, van Leeuwen FE, Diallo I, de Vathaire F, et al
    Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma.
    J Natl Cancer Inst. 2024 Nov 1:djae274. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
92. FOSTER VM, Trentham-Dietz A, Stout NK, Lee CI, et al
    Supplemental breast cancer screening after negative mammography in U.S. women with dense breasts.
    J Natl Cancer Inst. 2024 Oct 30:djae272. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. KJAERGAARD KA, Kousholt A, Thomsen RW, Woolpert KM, et al
    Risk of type-2-diabetes after breast cancer treatment: a population-based cohort study in Denmark.
    J Natl Cancer Inst. 2024 Oct 22:djae261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. KARLSSON P, Fyles A, Chang SL, Arrick B, et al
    Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
    J Natl Cancer Inst. 2024 Oct 18:djae262. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. ROMANOS-NANCLARES A, Schernhammer E, Willett WC, Holmes MD, et al
    Consumption of aspartame and risk of breast cancer in the Nurses' Health Studies.
    J Natl Cancer Inst. 2024 Oct 17:djae259. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. SHERMAN ME, Winham SJ, Vierkant RA, Mccauley BM, et al
    Polygenic risk scores stratify breast cancer risk among women with benign breast disease.
    J Natl Cancer Inst. 2024 Oct 16:djae255. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. JOHN EM, Koo J, Ingles SA, Keegan TH, et al
    Risk factors for second primary breast cancer by laterality, age, and race and ethnicity.
    J Natl Cancer Inst. 2024 Oct 11:djae254. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. WATTS EL, Moore SC, Abar L, Hong HG, et al
    Physical activity, metabolites, and breast cancer associations.
    J Natl Cancer Inst. 2024 Oct 9:djae246. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. CARROLL JE, Crespi CM, Cole S, Ganz PA, et al
    Transcriptomic markers of biological aging in breast cancer survivors: a longitudinal study.
    J Natl Cancer Inst. 2024 Oct 8:djae201. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2024
100. MARCZYK M, Kahn A, Silber A, Rosenblit M, et al
     Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017.
     J Natl Cancer Inst. 2024 Sep 30:djae241. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. PAGLIUCA M, Havas J, Thomas E, Drouet Y, et al
     Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.
     J Natl Cancer Inst. 2024 Sep 9:djae222. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. DAS S, Wentzensen N, Sawaya GF, Egemen D, et al
     Primary human papillomavirus testing vs cotesting: clinical outcomes in populations with different disease prevalence.
     J Natl Cancer Inst. 2024;116:1525-1529.
     PubMed     Abstract available
     
     
     
103. MANDELBLATT J, Dage JL, Zhou X, Small BJ, et al
     Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study.
     J Natl Cancer Inst. 2024;116:1495-1507.
     PubMed     Abstract available
     
     
     August 2024
104. ZHANG Y, Lindstrom S, Kraft P, Liu Y, et al
     Genetic Risk, Health-Associated Lifestyle, and Risk of Early-onset Total Cancer and Breast Cancer.
     J Natl Cancer Inst. 2024 Aug 27:djae208. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. EBRAHIMOGHLI R, Aghaei MH, Azami-Aghdash S, Houssami N, et al
     Uptake of Breast Cancer Screening Practices in Low and Middle-Income Countries: A Systematic Review and Meta-Analysis.
     J Natl Cancer Inst. 2024 Aug 12:djae187. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. FOLDI J, Carleton N, Anderson SJ, Rastogi P, et al
     Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials.
     J Natl Cancer Inst. 2024 Aug 10:djae188. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. MALAGON T
     Time to change the paradigm for primary endpoints in cancer screening trials?
     J Natl Cancer Inst. 2024;116:1187-1189.
     PubMed    
     
     
     July 2024
108. MASSA D, Vernieri C, Nicole L, Criscitiello C, et al
     Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer.
     J Natl Cancer Inst. 2024 Jul 31:djae178. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. HURSON AN, Ahearn TU, Koka H, Jenkins BD, et al
     Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.
     J Natl Cancer Inst. 2024 Jul 17:djae172. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
     Ovarian cancer risk factors in relation to family history.
     J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2024
111. DENT R, Cortes J, Pusztai L, McArthur H, et al
     Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study.
     J Natl Cancer Inst. 2024 Jun 24:djae129. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. JAGUST P, Powell AM, Ola M, Watson L, et al
     RET overexpression leads to increased brain metastatic competency in luminal breast cancer.
     J Natl Cancer Inst. 2024 Jun 10:djae091. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. CHUA AV JR, Sheng H, Liang E, Gandhi S, et al
     Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study.
     J Natl Cancer Inst. 2024 Jun 6:djae128. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. LIN J, Ouyang Y, Li Y, Jin L, et al
     Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer.
     J Natl Cancer Inst. 2024 Jun 4:djae115. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
115. 
     Correction to: Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy.
     J Natl Cancer Inst. 2024 May 8:djae093. doi: 10.1093.
     PubMed    
     
     
     
116. VO JB, Ramin C, Veiga LHS, Brandt C, et al
     Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors.
     J Natl Cancer Inst. 2024 May 8:djae107. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2024
117. OMOLEYE OJ, Esserman LJ, Olopade OI
     RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
     J Natl Cancer Inst. 2024;116:627-628.
     PubMed    
     
     
     
118. VILLY MC, Le Ven A, Le Mentec M, Masliah-Planchon J, et al
     Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
     J Natl Cancer Inst. 2024;116:580-587.
     PubMed     Abstract available
     
     
     
119. SANDOVAL RL, Bottosso M, Tianyu L, Polidorio N, et al
     TP53-associated early breast cancer: new observations from a large cohort.
     J Natl Cancer Inst. 2024 Apr 3:djae074. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
120. ZENG E, He W, Sjolander A, Bergqvist J, et al
     Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
     J Natl Cancer Inst. 2024 Mar 12:djae061. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. HUBBARD RA, Su YR, Bowles EJ, Ichikawa L, et al
     Predicting five-year interval second breast cancer risk in women with prior breast cancer.
     J Natl Cancer Inst. 2024 Mar 11:djae063. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. LEE CI, Elmore JG
     Beyond survival: a closer look at lead-time bias and disease-free intervals in mammography screening.
     J Natl Cancer Inst. 2024;116:343-344.
     PubMed    
     
     
     
123. KUMAR N, Ehsan S, Banerjee S, Fernandez Perez C, et al
     The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis.
     J Natl Cancer Inst. 2024 Mar 5:djae056. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2024
124. LI JL, McClellan JC, Zhang H, Gao G, et al
     Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.
     J Natl Cancer Inst. 2024 Feb 23:djae041. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum